The Eagle Biosciences’ Calprotectin ELISA Kit was utilized in a recent study! Scientists explored whether the repeated clearance of colon microbiome for regular screenings or surgeries changes the microbiome. Check out the abstract and access to the full text below.


Abstract

Chronic gastrointestinal diseases are a significant global health burden that can require the use of gastrointestinal-cleansing regimens for diagnostics or therapeutic treatment. These regimens are beneficial for facilitating surgical preparation, drug delivery, colorectal cancer screenings, and personal use is common among proponents of natural health and among certain populations at high risk of HIV acquisition. It remains unclear, however, whether repeated clearance of the colonic microbiome induces persistent changes in the microbiome, intestinal immunity, and viral disease susceptibility. We addressed these parameters by repeatedly administering iso-osmolar enemas to rhesus macaques prior to low-dose intra-rectal challenge with simian immunodeficiency virus (SIV). Considering both longitudinal and cross-sectional analyses, we observed no consistent changes in the fecal microbiome or intestinal immune parameters of treated animals, nor were significant differences observed in susceptibility to SIV acquisition. Unexpectedly, enema-treated animals exhibited significantly lower setpoint viral loads after infection, although we were unable to clearly identify attributing causes. Our study demonstrates that repeated microbiome clearance using clinically administered iso-osmolar enemas is not sufficient to restructure the fecal microbiome, perturb intestinal immune parameters, or increase susceptibility to mucosal SIV challenge. This research framework serves as a model for the development of colonic-administered diagnostics like Calprotectin ELISA and interventions.

Ortiz, Alexandra M. et al. Repeated enema administration in rhesus macaques is not sufficient to promote bacterial dysbiosis or gastrointestinal dysfunction. Mucosal Immunology, Volume 0, Issue 0. doi: 10.1016/j.mucimm.2025.06.002


If you have any questions about this Calprotectin ELISA assay kit or any of our other offerings, contact Eagle Biosciences here.

Serotonin Sensitive ELISA Kit


Abstract

Introduction: Serotonin (5-HT) is critical for neurodevelopment and the serotonin transporter (SERT) modulates serotonin levels. Perturbed prenatal and postnatal dietary exposures affect the developing offspring predisposing to neurobehavioral disorders in the adult. We hypothesized that the postnatal brain 5-HT-SERT imbalance associated with gut dysbiosis forms the contributing gut-brain axis dependent mechanism responsible for such ultimate phenotypes.

Methods: Employing maternal diet restricted (IUGR, n=8) and high fat+high fructose (HFhf, n=6) dietary modifications, rodent brain serotonin was assessed temporally by ELISA and SERT by quantitative Western blot analysis. Simultaneously, colonic microbiome studies were performed.

Results: At early postnatal (P) day 2 no changes in the IUGR, but a ~24% reduction in serotonin (p = 0.00005) in the HFhf group occurred, particularly in the males (p = 0.000007) revealing a male versus female difference (p = 0.006). No such changes in SERT concentrations emerged. At late P21 the IUGR group reared on HFhf (IUGR/HFhf, (n = 4) diet revealed increased serotonin by ~53% in males (p = 0.0001) and 36% in females (p = 0.023). While only females demonstrated a ~40% decrease in serotonin (p = 0.010), the males only trended lower without a significant change within the HFhf group (p = 0.146). SERT on the other hand was no different in HFhf or IUGR/RC, with only the female IUGR/HFhf revealing a 28% decrease (p = 0.036). In colonic microbiome studies, serotonin-producing Bacteriodes increased with decreased Lactobacillus at P2, while the serotonin-producing Streptococcus species increased in IUGR/HFhf at P21. Sex-specific changes emerged in association with brain serotonin or SERT in the case of Alistipase, Anaeroplasma, Blautia, Doria, Lactococcus, Proteus, and Roseburia genera.

Discussion: We conclude that an imbalanced 5-HT-SERT axis during postnatal brain development is sex-specific and induced by maternal dietary modifications related to postnatal gut dysbiosis. We speculate that these early changes albeit transient may permanently alter critical neural maturational processes affecting circuitry formation, thereby perturbing the neuropsychiatric equipoise.

Ye X et al. (2024) Brain serotonin and serotonin transporter expression in male and female postnatal rat offspring in response to perturbed early life dietary exposures. Front. Neurosci. 18:1363094. doi: 10.3389/fnins.2024.1363094


If you have any questions about this product or any of our other offerings, contact us here.


The Calprotectin ELISA Kit was utilized in a recent publication. Scientists investigated the impact of repeated microbiome elimination on intestinal immunity and disease susceptibility. Check out the abstract and access to the full text below.


Abstract

Chronic gastrointestinal diseases are a significant global health burden that can require the use of gastrointestinal-cleansing regimens for diagnostics or therapeutic treatment. These regimens are beneficial for facilitating surgical preparation, drug delivery, colorectal cancer screenings, and personal use is common among proponents of natural health and among certain populations at high risk of HIV acquisition. It remains unclear, however, whether repeated clearance of the colonic microbiome induces persistent changes in the microbiome, intestinal immunity, and viral disease susceptibility. We addressed these parameters by repeatedly administering iso-osmolar enemas to rhesus macaques prior to low-dose intra-rectal challenge with simian immunodeficiency virus (SIV). Considering both longitudinal and cross-sectional analyses, we observed no consistent changes in the fecal microbiome or intestinal immune parameters of treated animals, nor were significant differences observed in susceptibility to SIV acquisition. Unexpectedly, enema-treated animals exhibited significantly lower setpoint viral loads after infection, although we were unable to clearly identify attributing causes. Our study demonstrates that repeated microbiome clearance using clinically administered iso-osmolar enemas is not sufficient to restructure the fecal microbiome, perturb intestinal immune parameters, or increase susceptibility to mucosal SIV challenge. This research framework serves as a model for the development of colonic-administered diagnostics and interventions.

Ortiz, Alexandra M. et al. Repeated enema administration in rhesus macaques is not sufficient to promote bacterial dysbiosis or gastrointestinal dysfunction. Mucosal Immunology, Volume 0, Issue 0. doi: 10.1016/j.mucimm.2025.06.002


If you have any questions about this product or any of our other offerings, contact us here.

Eagle Biosciences is excited to partner with BPM and support the Fetuin A (PTM) ELISA (DNlite-DKD)!


About Fetuin A (PTM)

The unique Fetuin A post translation modifications measured in this assay were identified in a large-scale profiling of urinary proteomics. This new biomarker can help predict the kidney condition of diabetes patients, months to years in advanced. This urine test can help predict kidney decline or complications and potentially improve a patient with diabetic kidney disease quality of care.

Principle of the Fetuin A (PTM) ELISA

The Fetuin A (PTM) ELISA (unique Fetuin-A with specific post translational modification (PTM) for Diabetic Kidney Disease (DKD)) is a competitive immunoassay. In this Fetuin A (PTM) ELISA, calibrators or unknown urine samples are mixed with anti-unique PTM Fetuin-A monoclonal antibody (mAb), and then incubated in a microplate pre-bounded with unique PTM Fetuin-A. The monoclonal antibody recognizes unique PTM Fetuin-A in calibrators or unknown samples under competition in microplate wells. After an incubation, an Horseradish Peroxide (HRP) conjugated secondary antibody is added, followed by an incubation with 3,3’,5,5’-tetramethylbenzidine (TMB) substrate. Their relative reactivity is determined by absorbance measurement at 450 nanometers (nm) and plotted by comparison with a predetermined unique PTM Fetuin-A calibration curve.

Benefits of the Assay

    • Fewer Steps
    • Shorter processing times – ever for high-throughput samples

If you have any questions about this kit or any of our other offerings, contact us here.

Eagle Biosciences is excited to announce the newest product series for Host Cell Protein Detection!

Host cell proteins (HCPs) are a major class of impurities produced during biotherapeutic manufacturing. They must be removed from the final drug product to both assure patient safety and maintain drug efficacy. Our wide range of Host Cell Protein Detection Kits are easy to use and highly sensitive.


What are HCPs and why must they be removed from biologic drugs?

HCPs are proteins produced or encoded by the host organisms used to produce recombinant therapeutic proteins. Genetic engineering allows the host organism cells to be transformed to produce a protein of interest. During the recombinant protein production, host cells also coproduce proteins related to the normal cell functions such structural proteins, as well as proteins required for normal cellular growth and function, and vary in both number and concentration depending on the chosen host species and the manufacturing process being used. In general, apart from the therapeutic protein of interest, all endogenous proteins co-expressed by the host cells are called host-cell proteins.

Why must HCPs be removed from biologic drugs?

HCPs must be removed from the final biotherapeutic product to avoid adverse effects. Almost all HCPs carry safety risks as foreign proteins due to the potential to elicit immune response in humans (e.g, cytokine storm). In addition, some HCPs can also act to enhance the immune response to a drug product. Certain HCPs can also affect drug product stability and efficacy if not adequately removed or inactivated.

How are HCPs detected?

ELISAs are widely used for detecting HCPs, where they are generally configured in a sandwich assay format for improved specificity. In this scenario, a microplate-bound antibody is used for analyte capture, then a second analyte-specific antibody (that binds a different epitope on the target molecule) is added to enable detection. By incorporating a reference standard (e.g., a purified protein) into the assay design, it is possible to quantify the analyte of interest and confirm that its concentration meets regulatory requirements. Advantages of ELISA are that it is sensitive and compatible with high sample throughput – key considerations for biopharmaceutical manufacturing.


If you have any questions about these products or any of our other offerings, contact us here.


Fibroblast Growth Factor 23 (FGF-23) is a hormone primarily produced by osteocytes and osteoblasts in bones, playing a key role in regulating phosphate and vitamin D metabolism. It lowers serum phosphate levels by reducing phosphate reabsorption in the kidneys and suppresses the activation of vitamin D, thereby decreasing intestinal phosphate and calcium absorption. FGF-23 requires the co-receptor Klotho to bind to fibroblast growth factor receptors (FGFRs) and exert its effects, primarily in the kidneys. Dysregulation of FGF-23 is associated with several pathological conditions, making it a valuable biomarker for assessing phosphate balance and mineral metabolism.


image credit: https://www.kidney-international.org/


Why Measure FGF-23?

Measuring FGF-23 is essential for advancing research on phosphate metabolism, bone biology, and endocrine regulation. It provides insights into the mechanisms underlying phosphate homeostasis and the complex interplay between FGF-23, Klotho, and fibroblast growth factor receptors. FGF-23 is also a valuable marker for studying how mineral metabolism affects systemic processes, including cardiovascular function and aging. In experimental models, FGF-23 measurements help elucidate the effects of genetic mutations, dietary phosphate intake, and novel therapeutic interventions on phosphate regulation. Additionally, FGF-23 serves as a biomarker to explore the broader effects of mineral dysregulation on inflammation, oxidative stress, and metabolic disorders, enhancing our understanding of its role in health and disease.


Related Products:


*Use Promo Code: FGF25 to save 25% on your order!

We’re thrilled to announce that the MedFrontier Intact FGF23 Assay was featured in a recent publication! Details are available via the abstract and full-text access provided below.


Abstract

Multiple myeloma commonly manifests with symptoms arising from the involvement of various organs, particularly the bone and kidneys. In this report, we detail the case of a 44-year-old man who was diagnosed with multiple myeloma associated with reduced bone density. He exhibited clinical findings of osteomalacia due to Fanconi syndrome (characterized clinically by bone pain and proximal weakness and biochemically by elevated serum alkaline phosphatase, hypophosphatemia, hypouricemia, and glucosuria). With phosphate replacement, there was a notable improvement in bone pain, osteomalacia, and bone mineral density. Nevertheless, the patient continued to experience renal wasting of phosphate, uric acid, and glucose despite achieving remission from multiple myeloma for nearly 2 years. Our case highlights several important clinical features of myeloma-associated Fanconi syndrome, including the need to recognize this complication to appropriately treat the underlying bone disease while avoiding osteoclast inhibitors and the long-term persistence of the proximal renal tubulopathy despite achieving remission from myeloma and correction of osteomalacia.

Alireza Zomorodian, Naim M Maalouf, Long-term Evolution of Hypophosphatemia and Osteomalacia in a Patient With Multiple Myeloma, JCEM Case Reports, Volume 2, Issue 7, July 2024, luae137, https://doi.org/10.1210/jcemcr/luae137


If you have any questions about this product or any of our other offerings, contact us here.

Eagle Biosciences, Inc. is thrilled to announce a distribution partnership with Matriks Biotek, a leader in the development of ELISA kits for therapeutic drug monitoring!


About Matriks Biotek

Matriks Biotek was founded in 2002 by Prof. Haluk Ataoglu MD, PhD (Microbiology & Immunology). Their core business values include science, innovation, reliability, perfection and customer satisfaction. They were the first R&D company to globally commercialize ELISA kits for monitoring biological drugs, providing reliable tools for numerous research applications. With an offering of over 90 validated ELISA kits covering 36 biological drugs, Matriks Biotek’s product line includes quantitative free drug detection kits, qualitative anti-drug antibody detection kits, total antibody detection kits!

Key performance features of Matriks Biotek ELISA Kits:

  • Reliable Results: High recovery rates (85-115%) for robust results
  • Convenience: Minimal sample volume requirements (10-25 µl), even for small samples like mouse serum
  • Speed: Rapid processing times (70-140 minutes) for efficient workflows
  • Versatility: Broad sample compatibility (human, mouse, rat, and monkey serum or plasma)
  • Dynamic Range: Optimized for Cmax – Cmin (trough) values

Check out the full catalog, or reach out to us with any questions — we’d love to hear from you!

A recent publication employed the Bovine IgM ELISA Assay Kit to help measure the effects of commercial-scale heat treatments on milk proteins! This research provides key data on protein retention and functionality after processing. Check out the details and access the full findings below.


Abstract

Two pasteurization steps are often used in the preparation of whey protein concentrate (WPC) before evaporation into a dry product. The Pasteurized Milk Ordinance (PMO) in the United States requires that raw bovine milk be pasteurized using a process that meets minimum heat treatment requirements to achieve reductions in pertinent microorganisms. In addition, WPC produced from USDA-approved plants must comply with CFR Subpart B §58.809, which dictates that all fluid whey used in the manufacture of dry whey products shall be pasteurized before being condensed. These heat treatments are effective at inactivating the most thermally resistant bacterium, such as Coxiella burnetii; however, they can also alter milk proteins—inducing denaturation, aggregation and reduced bioactivity. Though the impact of thermal treatments on whey proteins has been examined, the specific influence of 2 high-temperature-short-time (HTST) pasteurization steps on the retention of proteins in WPC remains unknown. This study aimed to investigate the effect of commercial-scale HTST pasteurization of both raw milk and the resulting sweet whey on the products’ overall protein profile. Three distinct batches of raw milk (RM) and corresponding pasteurized milk (PM), the resulting whey (RW) and pasteurized whey (PW) produced at commercial scale were analyzed. Assessments of denaturation were conducted through solubility testing at pH 4.6 and hydrophobicity evaluation via anilinonaphthalene-1-sulfonic acid assay (ANS). Additionally, enzyme-linked immunosorbent assay (ELISA), PAGE (PAGE) and liquid chromatography tandem mass spectroscopy (LC-MS/MS) were employed to compare the retention of key bioactive proteins before and after each HTST pasteurization step. The percentage of soluble whey protein decreased from RM to PM and from RW to PW, but no significant differences were observed via hydrophobicity assay. ELISA revealed a significant reduction in key bioactive proteins, such as lactoferrin, immunoglobulin A and immunoglobulin M, but not immunoglobulin G, after HTST pasteurization of RM and RW. PAGE and LC-MS/MS revealed a significant decrease in the retention of lactoferrin and key milk fat globular membrane proteins, such as xanthine dehydrogenase oxidase/xanthine oxidase, lactadherin and fatty acid binding protein. Additionally, xanthine oxidase activity was significantly reduced after HTST pasteurization of milk and whey. This research helps to identify the limitations of the current processing techniques used in the dairy industry and could lead to innovation in improving the retention of bioactive proteins.

Haas, Joanna et al. Effects of high temperature short time (HTST) pasteurization on milk and whey during commercial whey protein concentrate production. Journal of Dairy Science, Volume 0, Issue 0. DOI: 10.3168/jds.2024-25493


If you have any questions about this kit or any of our other offerings, contact us here.

The Niacin Microtiter Plate Assay Kit was utilized in a recent study! Researchers developed a novel approach to study microglia, key immune cells in the CNS, under different conditions. Read on for a summary of this groundbreaking research!


Summary

Microglia are the resident macrophages of the central nervous system (CNS). Their phagocytic activity is central during brain development and homeostasis—and in a plethora of brain pathologies. However, little is known about the composition, dynamics, and function of human microglial phagosomes under homeostatic and pathological conditions. Here, we developed a method for rapid isolation of pure and intact phagosomes from human pluripotent stem cell-derived microglia under various in vitro conditions, and from human brain biopsies, for unbiased multiomic analysis. Phagosome profiling revealed that microglial phagosomes were equipped to sense minute changes in their environment and were highly dynamic. We detected proteins involved in synapse homeostasis, or implicated in brain pathologies, and identified the phagosome as the site where quinolinic acid was stored and metabolized for de novo nicotinamide adenine dinucleotide (NAD+) generation in the cytoplasm. Our findings highlight the central role of phagosomes in microglial functioning in the healthy and diseased brain.

Wogram, E et al. Rapid phagosome isolation enables unbiased multiomic analysis of human microglial phagosomes. Immunity. 57(9)p:2216-2231.e11 doi:10.1016/j.immuni.2024.07.019


If you have any questions about the Niacin Microtiter Plate Assay Kit or any of our other offerings, contact us here.